WallStSmart

Aclarion Inc (ACON)vsR1 RCM Inc (RCM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

R1 RCM Inc generates 3913641% more annual revenue ($2.46B vs $62,950). ACON leads profitability with a 0.0% profit margin vs -2.5%. RCM earns a higher WallStSmart Score of 39/100 (F).

ACON

Avoid

33

out of 100

Grade: F

Growth: 6.3Profit: 2.5Value: 5.0Quality: 6.5
Piotroski: 4/9

RCM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 6.7Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACON2 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
76.1%10/10

Revenue surging 76.1% year-over-year

RCM1 strengths · Avg: 8.0/10
Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Areas to Watch

ACON4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$3.58M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-88.3%2/10

ROE of -88.3% — below average capital efficiency

RCM4 concerns · Avg: 2.8/10
PEG RatioValuation
2.064/10

Expensive relative to growth rate

Operating MarginProfitability
3.8%3/10

Operating margin of 3.8%

Return on EquityProfitability
-2.2%2/10

ROE of -2.2% — below average capital efficiency

EPS GrowthGrowth
-99.3%2/10

Earnings declined 99.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : ACON

The strongest argument for ACON centers on Price/Book, Revenue Growth. Revenue growth of 76.1% demonstrates continued momentum.

Bull Case : RCM

The strongest argument for RCM centers on Price/Book. Revenue growth of 14.7% demonstrates continued momentum.

Bear Case : ACON

The primary concerns for ACON are EPS Growth, Market Cap, Profit Margin.

Bear Case : RCM

The primary concerns for RCM are PEG Ratio, Operating Margin, Return on Equity.

Key Dynamics to Monitor

ACON profiles as a hypergrowth stock while RCM is a turnaround play — different risk/reward profiles.

ACON carries more volatility with a beta of 1.43 — expect wider price swings.

ACON is growing revenue faster at 76.1% — sustainability is the question.

RCM generates stronger free cash flow (60M), providing more financial flexibility.

Bottom Line

RCM scores higher overall (39/100 vs 33/100) and 14.7% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aclarion Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Aclarion Inc (ACON) is an innovative healthcare technology company specializing in non-invasive diagnostic solutions that harness advanced data analytics and machine learning. By optimizing treatment pathways for musculoskeletal conditions, Aclarion delivers actionable insights derived from cutting-edge imaging techniques. Positioned at the forefront of the digital health sector, the company is addressing significant challenges in patient management while enhancing outcomes and reducing costs. Aclarion is well-positioned to capitalize on the growing demand for effective diagnostic tools in a dynamic healthcare landscape.

Visit Website →

R1 RCM Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

R1 RCM Inc (RCM) is a leading provider of technology-enabled revenue cycle management services, specializing in optimizing the financial performance of healthcare organizations. By leveraging advanced analytics and industry expertise, R1 RCM delivers comprehensive solutions that streamline patient billing processes and enhance operational efficiencies across a diverse portfolio of clients, including hospitals and outpatient facilities. The company's innovative approach not only improves revenue capture but also elevates the patient experience, positioning R1 RCM as a key player in the evolving healthcare landscape. With a robust growth strategy focused on expanding its service offerings and market reach, R1 RCM is poised to capitalize on the increasing demand for effective revenue cycle solutions in the healthcare sector.

Want to dig deeper into these stocks?